Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2018
At a glance
- Drugs Melphalan (Primary) ; Filgrastim; Palifermin
- Indications Multiple myeloma
- Focus Adverse reactions
- 09 May 2018 Planned number of patients changed from 90 to 60.
- 09 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.
- 02 Feb 2018 New trial record